Document is current

Article History

Received: 22 March 2025

Revised: 17 June 2025

Accepted: 17 June 2025

First Online: 3 July 2025

Declarations

:

: SM has received honoraria from AstraZeneca, AbbVie, Bristol Myers Squibb, Chugai, Genmab, Gilead, Nippon Shinyaku, Novartis, and Takeda. SF has received honoraria from Janssen, Ono Pharmaceutical, Genmab, AbbVie, Takeda, Nippon Shinyaku, Chugai, AstraZeneca, Otsuka, and Amgen and research funding from Chugai, Loxo Oncology, AbbVie, and Mitsubishi Tanabe Pharma. SF has also served on advisory boards for Genmab. WM has received honoraria from Chugai and research funding from Ono Pharmaceutical, Chugai, Nippon Shinyaku, and Genmab. HI has received research funding from Elekta K.K. SS has received honoraria from Ono Pharmaceutical. KI has received honoraria/fees from MSD, AstraZeneca, AbbVie, Bristol Myers Squibb, Novartis, Yakult, Kyowa Kirin, Chugai, BeiGene, Genmab, Otsuka, Ono Pharmaceutical, Mitsubishi Tanabe Pharma, Eisai, SymBio, Takeda, Zenyaku, Carna Biosciences, Nippon Shinyaku, Pfizer, Janssen, Daiichi Sankyo, Gilead, Nippon Kayaku, Lilly, Astellas, and Meiji Seika Pharma. KI has also received research funding from MSD, AstraZeneca, AbbVie, Incyte, Bristol Myers Squibb, Novartis, Bayer, Pfizer, Janssen, Yakult, Kyowa Kirin, Daiichi Sankyo, Chugai, BeiGene, Genmab, Loxo Oncology, Otsuka, Regeneron, and Gilead. The other authors declare no conflicts of interest.